Axsome Therapeutics, a biopharmaceutical company listed on NASDAQ under the ticker symbol AXSM, has recently disclosed that they have administered the first dose to a patient in the SUMMIT Phase 3 trial for AXS-05, a potential treatment for smoking cessation. This trial represents a significant advancement in the company's efforts to address central nervous system disorders. The development marks a crucial milestone in the research and development of new therapies, showcasing the company's dedication to innovation in the healthcare industry.
